Biotech | March 11, 2022
Moderna begins Phase 2 study of Omicron-specific bivalent booster
Moderna's Omicron-specific bivalent booster candidate combines its Omicron-specific booster candidate with its Covid-19 vaccine
Moderna's Omicron-specific bivalent booster candidate combines its Omicron-specific booster candidate with its Covid-19 vaccine
Partners with GITAM University to train 27 employees through a 10-day HR module and make them future-ready
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
The primary objective of this Phase 1 study is to investigate the safety and tolerability of GZR18 in healthy volunteers
As the world celebrates World Glaucoma Week (March 7-13th), Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals, an authority on eye diseases spoke to Thomas C Thottathil, Editor, indianpharmapost.com, on the seriousness of Glaucoma
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
The RI investment comes on the back of three other recently completed transactions in Malaysia and Singapore in the last two months
It has blended 36 important ingredients for a woman’s health, which has a mix of natural extracts, amino acids, multivitamins and minerals
The Gujarat Biotechnology policy released last month has made radical changes to position the state as a biotechnology hub. It already has a thriving ecosystem of pharma companies and varied suppliers
The team built a multiple ionic device system, each of which had a lithium cobalt oxide channel arranged on a common lithium phosphorus oxynitride electrolyte
Subscribe To Our Newsletter & Stay Updated
